Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 24, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis
Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, et al.
The Journal of Infectious Diseases
|
May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA
Tracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
Therapeutic Innovation & Regulatory Science
|
February 20, 2020
Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions
Greg Ball, Raffael Kurek, Barbara A Hendrickson, et al.
Journal of Gastroenterology and Hepatology
|
January 19, 2016
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea
Lai Wei, Tao Han, Dongliang Yang, et al.
The New England Journal of Medicine
|
March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Endocrine Journal
|
December 8, 2010
The relationship between serum thyrotropin and components of metabolic syndrome
Yaxin Lai, Jiani Wang, Fengwei Jiang, et al.
The Lancet. Respiratory Medicine
|
November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Conor D Tweed, Rodney Dawson, Divan A Burger, et al.
The New England Journal of Medicine
|
September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis
Francesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 24, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis
Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, et al.
The Journal of Infectious Diseases
|
May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA
Tracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
Therapeutic Innovation & Regulatory Science
|
February 20, 2020
Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions
Greg Ball, Raffael Kurek, Barbara A Hendrickson, et al.
Journal of Gastroenterology and Hepatology
|
January 19, 2016
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea
Lai Wei, Tao Han, Dongliang Yang, et al.
The New England Journal of Medicine
|
March 5, 2020
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie, Andreas H Diacon, Nosipho Ngubane, et al.
Endocrine Journal
|
December 8, 2010
The relationship between serum thyrotropin and components of metabolic syndrome
Yaxin Lai, Jiani Wang, Fengwei Jiang, et al.
The Lancet. Respiratory Medicine
|
November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Conor D Tweed, Rodney Dawson, Divan A Burger, et al.
The New England Journal of Medicine
|
September 2, 2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis
Francesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, et al.
Page
of 5